Amgen INC
Forward trial catalysts linked to AMGN
CSA tracks 10 forward catalysts for Amgen INC across 4 assets, spanning Phase 3. The nearest is a readout expected Jan 21, 2027 (day precision). Confidence across its tracked catalysts breaks down as 10 medium. Tracked indications include Vasculitis, Granulomatosis With Polyangiitis, Obesity, and 15 more.
AMGN in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Amgen INC has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
21 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| tarlatamab | NCT05740566 | Phase 3 | Active, not recruiting | 2025-01-29 | Experimental | Amgen | Small Cell Lung Cancer (SCLC) |
| sotorasib | NCT06497556 | Phase 3 | Active, not recruiting | 2026-05-19 | Active comparator | Hoffmann-La Roche | Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer |
| maridebart cafraglutide | NCT06858839 catalyst | Phase 3 | Active, not recruiting | 2027-01-21 | Experimental | Amgen | Obesity |
| maridebart cafraglutide | NCT06858878 | Phase 3 | Active, not recruiting | 2027-01-21 | Experimental | Amgen | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight |
| maridebart cafraglutide | NCT06987695 catalyst | Phase 3 | Active, not recruiting | 2027-04-27 | Experimental | Amgen | Obesity Disease |
| sotorasib | NCT05920356 catalyst | Phase 3 | Recruiting | 2027-06-30 | Experimental | Amgen | Non-Small Cell Lung Cancer (NSCLC) |
| tarlatamab | NCT06211036 catalyst | Phase 3 | Active, not recruiting | 2027-07-05 | Experimental | Amgen | Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer |
| avacopan | NCT06321601 catalyst | Phase 3 | Active, not recruiting | 2027-07-18 | Experimental | Amgen | Vasculitis |
| maridebart cafraglutide | NCT07226765 catalyst | Phase 3 | Active, not recruiting | 2027-08-30 | Experimental | Amgen | Obstructive Sleep Apnea |
| maridebart cafraglutide | NCT07225686 catalyst | Phase 3 | Active, not recruiting | 2027-09-03 | Experimental | Amgen | Obesity; Obstructive Sleep Apnea |
| tarlatamab | NCT07778316 catalyst | Phase 3 | Recruiting | 2027-09-24 | Experimental | Amgen | Small Cell Lung Cancer |
| maridebart cafraglutide | NCT07684144 catalyst | Phase 3 | Recruiting | 2027-12-26 | Experimental | Amgen | Obesity; Overweight; Diabetes Mellitus, Type 2 |
| maridebart cafraglutide | NCT07684235 | Phase 3 | Recruiting | 2027-12-26 | Experimental | Amgen | Obesity; Overweight |
| maridebart cafraglutide | NCT07575399 catalyst | Phase 3 | Recruiting | 2028-01-03 | Experimental | Amgen | Obesity or Overweight |
| maridebart cafraglutide | NCT07037433 | Phase 3 | Recruiting | 2028-06-30 | Experimental | Amgen | Atherosclerotic Cardiovascular Disease; Overweight; Obesity |
| maridebart cafraglutide | NCT07037459 | Phase 3 | Recruiting | 2028-06-30 | Experimental | Amgen | Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection… |
| sotorasib | NCT06252649 | Phase 3 | Recruiting | 2028-09-25 | Experimental | Amgen | Metastatic Colorectal Cancer |
| tarlatamab | NCT07005128 | Phase 3 | Active, not recruiting | 2029-01-04 | Experimental | Amgen | Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer |
| tarlatamab | NCT06117774 | Phase 3 | Active, not recruiting | 2030-04-20 | Experimental | Amgen | Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer |
| avacopan | NCT07176546 | Phase 2/3 | Recruiting | 2030-07 | Active comparator | Robert Spiera, MD | Granulomatosis With Polyangiitis; Wegener' s; GPA |
| tarlatamab | NCT07637513 | Phase 3 | Not yet recruiting | 2037-11 | Experimental | PrECOG, LLC. | Limited Stage Small-Cell Lung Cancer |
Every trial the CSA sample links to AMGN's tracked assets, including trials another sponsor runs and trials where the asset is not the experimental arm.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →